Home About us Current issue Back issues Submission Instructions Advertise Contact Login   

Search Article 
  
Advanced search 
 
Saudi Journal of Kidney Diseases and Transplantation
Users online: 4761 Home Bookmark this page Print this page Email this page Small font sizeDefault font size Increase font size 

BRIEF COMMUNICATION Table of Contents   
Year : 2018  |  Volume : 29  |  Issue : 3  |  Page : 637-642
Early initiation of angiotensin-converting enzyme inhibitors in postrenal transplant period: A study from a state-run tertiary care center


Department of Nephrology, Institute of Nephro-Urology, Victoria Hospital Campus, Bengaluru, Karnataka, India

Correspondence Address:
Umesh Lingaraju
Department of Nephrology, Institute of Nephro-Urology, Victoria Hospital Campus, Bengaluru, Karnataka
India
Login to access the Email id


DOI: 10.4103/1319-2442.235185

PMID: 29970741

Rights and Permissions

Angiotensin-converting enzyme inhibitors (ACEi) comprise a drug class, which are potent antihypertensives with renoprotective effects but are grossly underutilized in renal transplant recipients. These drugs have been reported to cause elevated potassium and creatinine levels in some renal transplant patients. There have been no reports of prospective studies on use of ACEi in renal transplant patients in the early post-transplant period. The purpose of this study is to assess the safety of an ACEi, when started in the early post-transplant period. In this prospective observational study, we reviewed 78 kidney transplant recipients during the period of January 2012 to March 2017 at our institution. Sixty-four patients were initiated on ACEi therapy within a month of transplantation, while 14 were initiated after one-month post-transplant; the latter was classified as late initiation group. Patients were enrolled when they met the following criteria: declining serum creatinine, improving urine output, and serum potassium <5.5 mEq/L. Exclusion criteria included anaphylaxis to ACEi, use of ACEi or angiotensin receptor blocker for the treatment of post-transplant erythrocytosis, and serum potassium >5.5 mEq/L. Sixty-four patients were studied, 53 (83%) were male and 11 (17%) were female. Mean age was 32 ± 15 years (12-56). Minimum duration of follow-up was six months. For each patient, hemoglobin, serum creatinine, and potassium levels were tested at the beginning of ACEi and at the end of the first, third, and the sixth month. The average potassium and hemoglobin levels did not differ significantly between the groups and were within the normal clinical ranges. While incidence of graft failure did not differ, death with functioning graft was lower in the ACEi group. ACEi can successfully be used in postrenal transplant with beneficial long-term impact on renal function. However, here is a need for further randomized controlled studies to validate this observation.


[FULL TEXT] [PDF]*
Print this article  Email this article
    

  Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
   Citation Manager
  Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1022    
    Printed11    
    Emailed0    
    PDF Downloaded103    
    Comments [Add]    

Recommend this journal